Search clinical trials for: AdimFlu-S Influenza Vaccine

Total 1120 results

Adimmune Corporation

Completed

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly Subjects

Influenza

Taiwan
Adimmune Corporation

Completed

The Safety and Immune Response to Influenza Vaccination in Pregnant Women

Influenza

Taiwan
National Cheng-Kung University Hospital

Unknown

The Effect and Safety of the Seasonal Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Not on Dialysis

Chronic Kidney Disease | Immunogenicity and Adverse Drug Effect of Vaccines Influenza

Taiwan
National Taiwan University Hospital

Unknown

Antibody Titer Analysis After H1N1 Vaccination in Pediatric Haemato-oncology Patients

Serology Analysis | Novel H1N1 Influenza Vaccination | Pediatric Haemato-oncology Patients

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Adults and Elders

Influenza

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Pediatric Population

Influenza

Taiwan
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older

Influenza (Healthy Volunteers)

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults

Pandemic Influenza

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Non-Elderly Adult and Elderly Subjects

Influenza
Fluart Innovative Vaccine Ltd, Hungary

Completed

Tolerability and Immunogenicity of Fluval P Monovalent Influenza Vaccine

Influenza

Hungary
Pfizer

Recruiting

A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza

Influenza | Vaccines | Grippe

United States
Adimmune Corporation

Completed

Immunogenicity and Safety of AdimFlu-S, Formulation 2010-2011, in Infants Aged Between 6-12months Old

Influenza

Taiwan
National Cheng-Kung University Hospital

Unknown

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine,Formulation 2011-2012, in Dialysis Patients

Influenza

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety Evaluation of QIS in Healthy Subjects

Influenza
Masonic Cancer Center, University of Minnesota

Terminated

Influenza Vaccine Post Allogeneic Transplant

Hematologic Malignancy | Hematopoietic Stem Cell Transplant

United States
Adimmune Corporation

Completed

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Healthy Subjects Aged Over 6 Months Old to 18 Years Old

Influenza
University of Rochester
National Institutes of Health (NIH)

Withdrawn

Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children (H1N1Children)

2009 H1N1 Influenza

United States
Emory University

Recruiting

Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

United States
Jiangsu Province Centers for Disease Control and...
Jiangsu Jindike Biotechnology Co., Ltd.

Completed

A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older

Influenza

China
University of Rochester
National Institutes of Health (NIH); Dartmouth-Hitchcock Medical Center

Completed

Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children

Influenza

United States
Shanghai Institute Of Biological Products

Completed

A Clinical Trial of A Quadrivalent Influenza Vaccine

Influenza

China
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above

Influenza

Germany
Sinovac Biotech Co., Ltd

Recruiting

A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months

Seasonal Influenza

China
Sinovac Biotech Co., Ltd

Completed

A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months

Seasonal Influenza

China
China National Biotec Group Company Limited
Peking University; Wuhan Institute of Biological Products Co., Ltd; Guizhou Center... and other collaborators

Completed

Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine

Enterovirus Infections | Influenza

China
Seqirus
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older

Influenza

Belgium
Institute of Vaccines and Medical Biologicals,...
Quintiles, Inc.; Department of Health and Human Services; National Institute... and other collaborators

Completed

Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) (IVACFLU-S)

Influenza, Human

Vietnam
Oriol Manuel
University of Zurich; University Hospital, Geneva; University Hospital, Basel... and other collaborators

Completed

Reducing the Burden of Influenza After Solid-Organ Transplantation (STOP-FLU)

Influenza | Organ Transplantation

Switzerland, Spain
Novartis Vaccines

Completed

Study to Evaluate Safety, Tolerability and Immunogenicity of a Bedside Mixing Combination of Two Adjuvanted Influenza Vaccines

Influenza

Switzerland
Novartis
Novartis Vaccines

Completed

Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine

Influenza Infection

Switzerland
Fluart Innovative Vaccine Ltd, Hungary

Completed

Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine in Adults and Elderly Persons

Influenza

Hungary
Seqirus

Completed

A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

Influenza, Human

United States
GlaxoSmithKline

Completed

Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1)

Influenza

France, Germany
University Hospital Inselspital, Berne
Merck Sharp & Dohme LLC; Boehringer Ingelheim; Abbott; Solvay Pharmaceuticals

Completed

Influenza Vaccination in Immunocompromized Patients

Immunosuppression

Switzerland
Shanghai Institute Of Biological Products

Completed

Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

Influenza

China
Marshfield Clinic Research Foundation
Centers for Disease Control and Prevention

Completed

Open-Label Influenza Vaccine Evaluation (OLIVE)

Immune Response

United States
Novartis Vaccines

Completed

Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years Old

Influenza

Dominican Republic
Novartis
Novartis Vaccines

Completed

Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old

Influenza

Argentina
Shiraz University of Medical Sciences

Completed

The Immunogenicity of Intradermal Influenza Vaccination in Hemodialysis Patients

Hemodialysis Patients

Iran, Islamic Republic of
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)

Influenza

Germany, Spain, United States, Korea, Republic of, Romania, Taiwan
Pfizer

Completed

A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older

Influenza, Human

United States, Brazil, South Africa, Philippines, New Zealand, Chile, Argentina
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children

Influenza

United States, Germany, Philippines, Czechia, France
Tel-Aviv Sourasky Medical Center

Unknown

Influenza Vaccination in Fibromyalgia Patients

Fibromyalgia Syndrome

Israel
University of Alabama at Birmingham

Recruiting

B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults

Influenza

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

COVID-19 Prevention

United States, Belgium, Poland
Centers for Disease Control and Prevention, China

Unknown

Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month

Influenza | Swine-origin A/H1N1 Influenza

China
Pfizer

Recruiting

A Study About Modified RNA Vaccines Against Influenza in Healthy Adults

Influenza, Human

United States
Protein Sciences Corporation

Completed

Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age

Influenza

United States
Protein Sciences Corporation
Kaiser Permanente

Completed

Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults

Human Influenza

United States
FluGen Inc

Completed

Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines

Influenza A

United States

3

Subscribe